Oyster Point Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.oysterpointrx.com
Clinical Trials
11
Active:0
Completed:10
Trial Phases
4 Phases
Phase 1:1
Phase 2:7
Phase 3:1
+1 more phases
Drug Approvals
2
NMPA:1
FDA:1
Drug Approvals
Varenicline Tartrate Nasal Spray
- Product Name
- 酒石酸伐尼克兰鼻喷雾剂
- Approval Number
- 国药准字HJ20240138
- Approval Date
- Nov 22, 2024
NMPA
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (63.6%)Phase 4
2 (18.2%)Phase 1
1 (9.1%)Phase 3
1 (9.1%)A Study Evaluating the Safety of the Nasal Pump
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06329687
- Locations
- 🇺🇸
United States, California, Newport Beach, California, United States
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
Phase 4
Completed
- Conditions
- Dry EyeKeratoconjunctivitis Sicca
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05918406
- Locations
- 🇺🇸
United States, New Jersey, Woodland Park, New Jersey, United States
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
Phase 2
Completed
- Conditions
- Neurotrophic Keratopathy
- Interventions
- Drug: OC-01 (varenicline) nasal spray 1.2 mg/mlDrug: Placebo (vehicle) nasal spray
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT04957758
- Locations
- 🇺🇸
Dothan Alabama, Dothan, Alabama, United States
🇺🇸Irvine, California, Irvine, California, United States
🇺🇸Los Angeles California, Los Angeles, California, United States
Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mgDrug: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04072146
- Locations
- 🇺🇸
United States, Miami Florida, Miami, Florida, United States
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Phase 3
Completed
- Conditions
- Dry Eye Disease (DED)
- Interventions
- Drug: OC-01 (varenicline) nasal sprayDrug: Placebo (vehicle) nasal spray
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 758
- Registration Number
- NCT04036292
- Locations
- 🇺🇸
Phoenix, Phoenix, Arizona, United States
🇺🇸New Port Beach, Newport Beach, California, United States
🇺🇸Fort Collins, Fort Collins, Colorado, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found